Characterization and Immunogenicity of HIV Envelope gp140 Zera® Tagged Antigens

HIV-1 envelope glycoprotein (Env) remains the most relevant target for the elicitation of functional antibodies to HIV by vaccination. However, soluble Env antigens often do not elicit the desired immune responses. Delivering subunit antigens on particulate nanoparticles is an established approach t...

Full description

Bibliographic Details
Main Authors: Phindile Ximba, Rosamund Chapman, Ann E. Meyers, Emmanuel Margolin, Michiel T. van Diepen, Anna-Lise Williamson, Edward P. Rybicki
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-04-01
Series:Frontiers in Bioengineering and Biotechnology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fbioe.2020.00321/full
id doaj-d86c002d4a024480833e43e37108f00d
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Phindile Ximba
Phindile Ximba
Phindile Ximba
Rosamund Chapman
Rosamund Chapman
Ann E. Meyers
Emmanuel Margolin
Emmanuel Margolin
Emmanuel Margolin
Michiel T. van Diepen
Michiel T. van Diepen
Anna-Lise Williamson
Anna-Lise Williamson
Edward P. Rybicki
Edward P. Rybicki
spellingShingle Phindile Ximba
Phindile Ximba
Phindile Ximba
Rosamund Chapman
Rosamund Chapman
Ann E. Meyers
Emmanuel Margolin
Emmanuel Margolin
Emmanuel Margolin
Michiel T. van Diepen
Michiel T. van Diepen
Anna-Lise Williamson
Anna-Lise Williamson
Edward P. Rybicki
Edward P. Rybicki
Characterization and Immunogenicity of HIV Envelope gp140 Zera® Tagged Antigens
Frontiers in Bioengineering and Biotechnology
HIV-1
protein body
envelope protein
vaccine
Zera®
immunogenicity
author_facet Phindile Ximba
Phindile Ximba
Phindile Ximba
Rosamund Chapman
Rosamund Chapman
Ann E. Meyers
Emmanuel Margolin
Emmanuel Margolin
Emmanuel Margolin
Michiel T. van Diepen
Michiel T. van Diepen
Anna-Lise Williamson
Anna-Lise Williamson
Edward P. Rybicki
Edward P. Rybicki
author_sort Phindile Ximba
title Characterization and Immunogenicity of HIV Envelope gp140 Zera® Tagged Antigens
title_short Characterization and Immunogenicity of HIV Envelope gp140 Zera® Tagged Antigens
title_full Characterization and Immunogenicity of HIV Envelope gp140 Zera® Tagged Antigens
title_fullStr Characterization and Immunogenicity of HIV Envelope gp140 Zera® Tagged Antigens
title_full_unstemmed Characterization and Immunogenicity of HIV Envelope gp140 Zera® Tagged Antigens
title_sort characterization and immunogenicity of hiv envelope gp140 zera® tagged antigens
publisher Frontiers Media S.A.
series Frontiers in Bioengineering and Biotechnology
issn 2296-4185
publishDate 2020-04-01
description HIV-1 envelope glycoprotein (Env) remains the most relevant target for the elicitation of functional antibodies to HIV by vaccination. However, soluble Env antigens often do not elicit the desired immune responses. Delivering subunit antigens on particulate nanoparticles is an established approach to improve their immunogenicity. In this study the sequence encoding Zera®, a proline-rich domain derived from the γ-zein storage protein, was fused to either the C- or N-terminus of the superinfecting HIV-1 CAP256 gp140 envelope: Zera® generally induces the formation of protein bodies (PBs), which can significantly improve both the immunogenicity and yields of the partner protein. The expression of gp140-Zera® and Zera®-gp140 (N- and C-terminal fusions respectively) in mammalian cells was confirmed by western blot analysis and immunostaining. However, isopycnic ultracentrifugation showed that neither gp140-Zera® nor Zera®-gp140 accumulated in characteristic electron-dense PBs. gp140-Zera® elicited higher binding antibody titers in rabbits to autologous gp140 and V1V2 scaffold than Zera®-gp140. Rabbit anti-gp140-Zera® sera also had significantly higher Tier 1A neutralizing antibody titers than anti-Zera®-gp140 sera. Neither gp140-Zera® nor Zera®-gp140-specific sera neutralized Tier 1B or autologous Tier 2 viruses. These results showed that HIV-1 gp140 tagged with Zera® at either the N- or C-termini elicited high titers of gp140 and V1V2 binding antibodies, and low levels of Tier 1 neutralizing antibodies in rabbits.
topic HIV-1
protein body
envelope protein
vaccine
Zera®
immunogenicity
url https://www.frontiersin.org/article/10.3389/fbioe.2020.00321/full
work_keys_str_mv AT phindileximba characterizationandimmunogenicityofhivenvelopegp140zerataggedantigens
AT phindileximba characterizationandimmunogenicityofhivenvelopegp140zerataggedantigens
AT phindileximba characterizationandimmunogenicityofhivenvelopegp140zerataggedantigens
AT rosamundchapman characterizationandimmunogenicityofhivenvelopegp140zerataggedantigens
AT rosamundchapman characterizationandimmunogenicityofhivenvelopegp140zerataggedantigens
AT annemeyers characterizationandimmunogenicityofhivenvelopegp140zerataggedantigens
AT emmanuelmargolin characterizationandimmunogenicityofhivenvelopegp140zerataggedantigens
AT emmanuelmargolin characterizationandimmunogenicityofhivenvelopegp140zerataggedantigens
AT emmanuelmargolin characterizationandimmunogenicityofhivenvelopegp140zerataggedantigens
AT michieltvandiepen characterizationandimmunogenicityofhivenvelopegp140zerataggedantigens
AT michieltvandiepen characterizationandimmunogenicityofhivenvelopegp140zerataggedantigens
AT annalisewilliamson characterizationandimmunogenicityofhivenvelopegp140zerataggedantigens
AT annalisewilliamson characterizationandimmunogenicityofhivenvelopegp140zerataggedantigens
AT edwardprybicki characterizationandimmunogenicityofhivenvelopegp140zerataggedantigens
AT edwardprybicki characterizationandimmunogenicityofhivenvelopegp140zerataggedantigens
_version_ 1724845969757962240
spelling doaj-d86c002d4a024480833e43e37108f00d2020-11-25T02:26:36ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852020-04-01810.3389/fbioe.2020.00321512410Characterization and Immunogenicity of HIV Envelope gp140 Zera® Tagged AntigensPhindile Ximba0Phindile Ximba1Phindile Ximba2Rosamund Chapman3Rosamund Chapman4Ann E. Meyers5Emmanuel Margolin6Emmanuel Margolin7Emmanuel Margolin8Michiel T. van Diepen9Michiel T. van Diepen10Anna-Lise Williamson11Anna-Lise Williamson12Edward P. Rybicki13Edward P. Rybicki14Division of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South AfricaBiopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Cape Town, South AfricaInstitute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South AfricaDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South AfricaInstitute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South AfricaBiopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Cape Town, South AfricaDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South AfricaBiopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Cape Town, South AfricaInstitute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South AfricaDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South AfricaInstitute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South AfricaDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South AfricaInstitute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South AfricaBiopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Cape Town, South AfricaInstitute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South AfricaHIV-1 envelope glycoprotein (Env) remains the most relevant target for the elicitation of functional antibodies to HIV by vaccination. However, soluble Env antigens often do not elicit the desired immune responses. Delivering subunit antigens on particulate nanoparticles is an established approach to improve their immunogenicity. In this study the sequence encoding Zera®, a proline-rich domain derived from the γ-zein storage protein, was fused to either the C- or N-terminus of the superinfecting HIV-1 CAP256 gp140 envelope: Zera® generally induces the formation of protein bodies (PBs), which can significantly improve both the immunogenicity and yields of the partner protein. The expression of gp140-Zera® and Zera®-gp140 (N- and C-terminal fusions respectively) in mammalian cells was confirmed by western blot analysis and immunostaining. However, isopycnic ultracentrifugation showed that neither gp140-Zera® nor Zera®-gp140 accumulated in characteristic electron-dense PBs. gp140-Zera® elicited higher binding antibody titers in rabbits to autologous gp140 and V1V2 scaffold than Zera®-gp140. Rabbit anti-gp140-Zera® sera also had significantly higher Tier 1A neutralizing antibody titers than anti-Zera®-gp140 sera. Neither gp140-Zera® nor Zera®-gp140-specific sera neutralized Tier 1B or autologous Tier 2 viruses. These results showed that HIV-1 gp140 tagged with Zera® at either the N- or C-termini elicited high titers of gp140 and V1V2 binding antibodies, and low levels of Tier 1 neutralizing antibodies in rabbits.https://www.frontiersin.org/article/10.3389/fbioe.2020.00321/fullHIV-1protein bodyenvelope proteinvaccineZera®immunogenicity